ATG 002

Drug Profile

ATG 002

Alternative Names: ATG-002

Latest Information Update: 06 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CoMentis
  • Class Small molecules
  • Mechanism of Action Angiogenesis inducing agents; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 07 Aug 2007 Discontinued - Phase-I/II for Diabetic foot ulcer in USA (Topical)
  • 21 Jun 2006 Athenagen has filed an IND with the US FDA for diabetic foot ulcers
  • 31 May 2006 Phase-I/II clinical trials in Diabetic foot ulcer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top